Inotiv is a diagnostics & research business based in the US. Inotiv shares (NOTV) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.21 – an increase of 17.58% over the previous week. Inotiv employs 1,955 staff and has a trailing 12-month revenue of around $501.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.21 |
|---|---|
| 52-week range | $1.23 - $11.42 |
| 50-day moving average | $1.86 |
| 200-day moving average | $3.47 |
| Wall St. target price | $5.33 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.84 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.79 from 2024-11-19
| 1 week (2024-11-13) | -2.45% |
|---|---|
| 1 month (2024-10-18) | 62.21% |
| 3 months (2024-08-20) | 76.58% |
| 6 months (2024-05-20) | 51.63% |
| 1 year (2023-11-20) | 22.91% |
|---|---|
| 2 years (2022-11-18) | -51.48% |
| 3 years (2021-11-19) | 57.88 |
| 5 years (2019-11-20) | 3.83 |
Valuing Inotiv stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Inotiv's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Inotiv's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $19 million.
The EBITDA is a measure of a Inotiv's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $501.1 million |
|---|---|
| Gross profit TTM | $157.2 million |
| Return on assets TTM | -2.92% |
| Return on equity TTM | -43.15% |
| Profit margin | -19.8% |
| Book value | $7.00 |
| Market Capitalization | $71 million |
TTM: trailing 12 months
We're not expecting Inotiv to pay a dividend over the next 12 months.
Over the last 12 months, Inotiv's shares have ranged in value from as little as $1.227 up to $11.4166. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inotiv's is 3.374. This would suggest that Inotiv's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.